RxDoctor Payments Data

Caren Singer, MD

Internal Medicine · Ft Lauderdale, FLNPI 1528020831

Payments from drug & device makers

$9,600in general payments, 2019–2025

Across 439 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Actelion Pharmaceuticals US, Inc.$996
  • Harmony Biosciences LLC$699
  • Boehringer Ingelheim$603
  • Regeneron Healthcare Solutions, Inc.$496
  • Insmed, Inc.$453
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$9,600100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,600 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$77,103
Medicare patients
233
Services billed
877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$70,030
XareltoRivaroxaban50$49,152
MounjaroTirzepatide40$47,177
EntrestoSacubitril/Valsartan32$46,095
FarxigaDapagliflozin Propanediol29$34,207
OzempicSemaglutide24$22,812
JardianceEmpagliflozin14$20,616
JanuviaSitagliptin Phosphate15$15,566
Breo ElliptaFluticasone/Vilanterol36$14,545
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,761
JanumetSitagliptin Phos/Metformin Hcl11$9,541
AmbienZolpidem Tartrate14$8,373
SynthroidLevothyroxine Sodium73$7,875
PaxlovidNirmatrelvir/Ritonavir33$7,147
Mesalamine14$5,943

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$341$77,177102 claims
Lilly USA, LLCMounjaro$142$47,17740 claims
NovartisEntresto$66$46,09532 claims
AstraZenecaFarxiga$440$34,20729 claims
GSKBreo Ellipta, Trelegy Ellipta$1,624$25,30651 claims
MerckJanuvia, Janumet$21$25,10826 claims
Novo NordiskOzempic$36$22,81224 claims
Boehringer IngelheimJardiance$603$20,61614 claims
AbbVieSynthroid$42$7,87573 claims
ANI Pharmaceuticals, Inc.Valsartan$28$1,46379 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Ft Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →